SM Entertainment’s Planned Sale of KeyEast Falls Through Again

Reporter Kim Jisun / approved : 2025-12-22 05:03:03
  • -
  • +
  • 인쇄

Photo: SM Entertainment

 

 

[Alpha Biz= Kim Jisun] SM Entertainment’s attempt to sell its drama production subsidiary KeyEast has collapsed for the second time this year, as concerns over the buyer’s funding capacity materialized. The repeated failures are expected to complicate efforts to find a new owner in the near term.

According to a filing with South Korea’s Financial Supervisory Service on the 21st, KeyEast disclosed that its share sale agreement with SM Entertainment and ERO Investment Fund No.1 was terminated due to the buyer’s failure to pay the remaining balance.

Under the agreement signed in October, SM was to sell a 33.71% stake in KeyEast (6.59 million shares) for KRW 34 billion. However, the buyer failed to pay the remaining KRW 27.2 billion by the transaction’s closing date on December 18, prompting SM to cancel the deal.

The breakdown had been widely anticipated, as ERO Investment Fund No.1 is a newly established entity with an unclear funding source, raising doubts about its ability to finance the acquisition. The transaction schedule had already been revised once to allow additional time for payment.

KeyEast’s prolonged earnings weakness has also weighed on the sale. The company has posted net losses for five consecutive years, including KRW 11 billion last year and KRW 3 billion in cumulative losses as of the third quarter this year.

 

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

어플

주요기사

Stellantis Considers Exit from U.S. Battery Joint Venture 'StarPlus Energy' with Samsung SDI2026.02.11
Yanolja Becomes Largest Shareholder of Modetour Ahead of General Shareholder Meeting2026.02.11
Court Acquits Sampyo Group Chairman in Landmark Serious Accidents Punishment Act Case; Labor Unions Decry "License to Kill"2026.02.11
Court Acquits LG Welfare Foundation CEO Koo Yeon-kyung and Husband Yoon Kwan in Insider Trading Case2026.02.11
Concerns Grow Over Possible Drug Mix-Up in Daewoong Pharmaceutical’s Hypertension Medicine as Recall Details Remain Unclear2026.02.11
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

HEADLINE

PHOTO

많이 본 기사